Pricing

Marker Therapeutics Inc (MRKR)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Peter L. Hoang
Employees:
60
4551 KENNEDY COMMERCE DR., HOUSTON, TX, 77032
(713) 400-6400
    Formally known as:
  • TapImmune Inc
  • TAPIMMUNE INC NEW COM STK (NV)
  • TAPIMMUNE INC NEW COMMON STOCK
  • TAPIMMUNE INC. NEW COMMON STOCK
Stock Split History
DateRatio
2001-06-08 1:5
2007-06-28 10:25
2009-07-27 1:1
2014-02-25 1:100
2016-09-16 1:12
2023-01-27 1:10
Marker Therapeutics, Inc. engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors. It is also developing TPIV100/110 and TPIV200, which is in Phase 2 clinical trials for breast and ovarian cancers.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available